1833 / 1851
Toxicity of concurrent SRT and
tyrosine kinase inhibitors (TKIs)
EGF-R-inhibitors (gefitinib, erlotinib, lapatinib)
Concurrent EGF-R-targeting TKIs and extra-cranial SRT:
increased toxicity within the irradiated volume
in the
treatment of abdominal and thoracic metastases
No increased toxicity in cranial SRT
Data on lapatinib+SRT is not available.
Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37